Biotech News
Related news
RVMDRevolution Medicines2026-08-10 10:01 EST
Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration
CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
BMEABiomea Fusion2026-06-03 12:00 EST
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
IDYAIDEAYA Biosciences2026-08-19 10:00 EST
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
BMYBMYBristol-Myers Squibb Company2026-06-08 10:59 EST
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
INBXInhibrx2026-07-16 13:00 EST
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
KYMRKymera2026-06-09 11:00 EST
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
IDYAIDEAYA Biosciences2026-07-17 13:00 EST
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
ELVNEnliven Therapeutics2026-06-15 20:40 EST
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Merus
Merus is a clinical-stage antibody company focused on precision oncology and bispecific antibody development. Its platform is built around engineered immunology and cancer programs.
Recent company news
MRUSMerus2025-12-12 07:54 EST
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
MRUSMerus2025-11-17 12:15 EST
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
MRUSMerus2025-10-24 14:00 EST
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
MRUSMerus2025-10-14 11:30 EST
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
MRUSMerus2025-10-13 16:00 EST
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Stock data
- Close
- —
- Market cap
- —
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States